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Low concentrations of plasma high-density lipoprotein (HDLs) are characteristic in metabolic syndrome (MS). The antioxidant
ability of HDLs is, at least in part, attributable to pleiotropic serum paraoxonase (PON1). Diﬀerent PON1 activities have been
assessed in 293 subjects with (n = 88) or without MS (n = 205) and with (n = 195) or without (n = 98) angiographically
proven coronary artery disease (CAD). MS subjects had low PON1 activities, with a progressively decreasing trend by increasing
thenumberofMSabnormalities.Theactivityversus7-O-diethylphosphoryl,3-cyano,4-methyl,7-hydroxycoumarin (DEPCyMC),
which is considered a surrogate marker of PON1 concentration, showed the most signiﬁcant association with MS, independently
of both HDL and apolipoprotein A-I levels. Subjects with MS and low DEPCyMCase activity had the highest CAD risk (OR 4.34
with 95% CI 1.44–13.10), while no signiﬁcant increase of risk was found among those with MS but high DEPCyMCase activity
(OR 1.45 with 95% CI 0.47–4.46). Our results suggest that low PON1 concentrations are typical in MS and may modulate the
MS-related risk of CAD.
1.Introduction
Metabolic syndrome (MS) deﬁnes a well-known cluster of
metabolic disturbances associated with an increased risk of
cardiovascular disease and diabetes [1–3]. Insulin resistance
is thought to be the core of MS [2, 3]. Nonetheless, oxidative
stress pathways have been also proposed to play a role in
MS. An increased oxidative stress, as well as a reduction
of antioxidant defences, may impair insulin signalling,
therefore leading per se to insulin resistance [4]. Moreover,
the crucial role of oxidative damage is well documented in
bothendothelialdysfunctionandatherosclerosisprocessesas
it is also accepted that the imbalance of reduction-oxidation
(redox) homeostasis may contribute to the development of
cardiovascular diseases in MS [4, 5].
Low levels of high-density lipoprotein (HDL) are typical
of the biochemical cluster deﬁning MS. HDLs are one of the
most important antioxidant defence systems in plasma. They
are well known to prevent low-density lipoprotein (LDL)
oxidation and protect against LDL-induced cytotoxicity [6–
9]. HDLs also possess anti-inﬂammatory properties, includ-
ing the ability of suppressing cytokine-induced endothelial
cell adhesion molecules function [10–12]. The antioxidant
propertiesofHDLsare,atleasttosomeextent,attributableto
serum paraoxonase (PON1). PON1 is a 45kDa, 355-amino-
acid glycoprotein which is synthesized essentially by the liver
and then secreted into the blood, where it links to HDLs
[13, 14]. PON1 is a pleiotropic enzyme, whose name origi-
nally derives from its capacity to neutralize highly toxic,
xenobiotic compounds, such as paraoxon. The physiological2 Experimental Diabetes Research
substrates of PON1, however, are yet partially undeﬁned,
even if convincing evidence points to a principal role of
PON1 as lactonase, with lipophylic lactones as the primary
substrates [15–17]. Previous studies by measuring the rate
of paraoxon hydrolysis have shown that subjects with MS
had lower PON1 activity [18, 19]. However, it is not clear
to what extent the classical, but not physiological, assay,
such as the paraoxonase activity, reﬂects the actual antiox-
idant capacity of the enzyme. Recently, novel PON1 assays
have been developed: 5-thiobutyl butyrolactone (TBBL)
and 7-O-diethyl phosphoryl 3-cyano 4-methyl 7-hydroxy-
coumarin (DEPCyMC) [20]. Both TBBLase and DEPCyM-
Case activities in sera are highly speciﬁc to PON1. TBBL
is a chromogenic lactone that resembles the most favo-
urable PON1 lactone substrates, allowing a speciﬁc eval-
uation of PON1 lactonase activity. The DEPCyMC is a
chromogenic phosphotriester substrate that, diﬀerently from
the other methods for PON1 activities, allows estimating
total PON1 concentration, the DEPCyMCase assay being
not inﬂuenced by the degree of catalytic stimulus by HDL.
The ratio between these two activities (TBBL-to-DEPCyMC
activity ratio) has been suggested to provide the so-called
“normalizedlactonaseactivity”(NLA),whichmayreﬂectthe
level of PON1 lactonase catalytic stimulation by HDL [20].
In a previous work, we showed for the ﬁrst time that these
novel PON1 activity assays may be associated with coronary
artery disease (CAD). More precisely, we observed that
CAD patients had low PON1 concentration, deﬁned by low
DEPCyMCase activity, but presented high stimulation of
PON1 lactonase activity, as indicated by high NLA values
[21].
The aim of this study was to evaluate PON1 activities
by means of both traditional (i.e., paraoxonase and aryles-
terase activity) and new assays (i.e., TBBLase and DEPCyM-
Case activity) in a population of subjects with or without
angiographically conﬁrmed CAD, according to either the
presence or absence of MS diagnosis. The potential interac-
tionbetweenMSandPON1activityasadeterminantofCAD
risk was also assessed.
2.MaterialsandMethods
2.1. Study Population. This study was performed within
the framework of the Verona Heart Project, a regional
survey designed for identiﬁcation of new risk factors for
CAD in subjects with objective angiographic documentation
of their coronary vessels. Details about enrolment criteria
have been described in detail elsewhere [22]. As previously
reported, a total of 300 subjects were selected and divided
into three subgroups matched for sex and age: CAD-free,
CAD without myocardial infarction (MI), and CAD with
MI [21]. CAD-free (n = 100) group had completely normal
coronary arteries, being submitted to coronary angiography
for reasons other than CAD, mainly valvular heart disease.
These controls were also required to have neither history
nor clinical or instrumental evidence of atherosclerosis in
vascular districts beyond the coronary bed. Two-hundred
subjects had angiographically proven CAD with at least
one of the main epicardial coronary arteries aﬀected (left
anteriordescending,circumﬂex,orright)with ≥1signiﬁcant
stenosis (≥50%). CAD patients were classiﬁed into MI
(n = 100) and non-MI (n = 100) subgroups on the
basis of a thorough review of medical records including his-
tory, electrocardiogram, enzyme changes, and/or the typical
sequelae of MI on ventricular angiography. The angiograms
were assessed by cardiologists who were unaware that the
patients were to be included in the study. All participants
came from the same geographical area (Northern Italy).
At the time of blood sampling, a complete clinical history
was collected, including the assessment of cardiovascular
risk factors such as obesity, smoking, hypertension, and
diabetes. From these 300 subjects we further selected 293
subjects (195 CAD and 98 CAD-free) for whom complete
data for MS diagnosis were available. According to the
established criteria [23], patients were classiﬁed as having
MS when at least three of the following conditions were
present: body mass index >30kg/m2;d o c u m e n t e dh i s t o r y
of hypertension or blood pressure >140/90mmHg; fasting
glucose >6.1mmol/L; plasma triglycerides >1.7mmol/L;
HDL <1.03mmol/L for males or <1.29mmol/L for fem-
ales.
The study was approved by the Ethic Committee of our
Institution (Azienda Ospedaliera, Verona). A written infor-
med consent was obtained from all the participants after a
full explanation of the study.
2.2. Biochemical Analysis. S a m p l e so fv e n o u sb l o o dw e r e
withdrawn from each subject, after an overnight fast. Serum
lipids and the other common biochemical parameters were
determined by routine methods. Apolipoprotein A-I (Apo
A-I) and Apolipoprotein B (Apo B) were measured by com-
mercially available nephelometric immunoassays; antisera,
calibrators, and the BNII nephelometer were from Dade
Behring [21]. LDL cholesterol/Apo B ratio was calculated as
surrogate marker of small and dense LDL particles [19].
2.3. PON1 Activity Assays. PON1 activity assays were per-
formed as previously described [20]. TBBL and DEPCyMC
were kindly provided by Dan Tawﬁk (Department of Bio-
logical Chemistry, Weizmann Institute of Science, Rehovot,
Israel).
Lactonase activity was measured in activity buﬀer
(50mM Tris pH 8.0, 1mM CaCl2) containing 0.25mM
of TBBL and 0.5mM 5,5 -dithio-bis-2-nitrobenzoic acid
(DTNB) by monitoring the absorbance at 412nm in a ﬁnal
volume of 200μL( C= 7,000OD/M), using an automated
microplate reader. The serum was diluted 400-fold in 100μL
of activity buﬀer complemented with 1mM DTNB. DTNB
wasusedfrom100mMstockinDMSO.TBBLwasusedfrom
250mM stock in acetonitrile. TBBL was diluted 500-fold in
activity buﬀer containing 2% acetonitrile. The reaction was
initiated by adding 100μL of TBBL (0.5mM) to 100μLo f
sera dilution. The ﬁnal sera dilution was 800-fold. All the
reaction mixtures contained a ﬁnal 1% acetonitrile. Rates of
spontaneous hydrolysis of TBBL in buﬀer were subtracted
from all the measurements. Activities were expressed as
U/mL (1 unit = 1μmol of TBBL hydrolyzed per minute per
1mL of undiluted serum).Experimental Diabetes Research 3
Total PON1 concentrations in human sera were assessed
bymeasuringtheactivitywithDEPCyMC.Fortheenzymatic
measurements, DEPCyMC was used from 100mM stock in
DMSO, and all the reaction mixtures contained a ﬁnal 1%
DMSO. The activity was measured with 10μLo fs e r u ma n d
1mM substrate in 50mM bis-tris-propane, pH 9.0, with
1mMCaCl 2, by monitoring the absorbance at 400nm in a
ﬁnal volume of 200μL( C= 22,240OD/M). Activities were
expressed as mU/mL (1milliunit = 1nmol of DEPCyMC
hydrolyzed per minute per 1mL of undiluted serum).
The normalized lactonase activity (NLA) was calculated
bydividingTBBLaseactivityofeachsamplebyitsDEPCyMC
activity.
Paraoxonase activity in sera samples was measured in
activity buﬀer with 1mM paraoxon by monitoring the
absorbance at 405nm (C = 10,515OD/M). Arylesterase
activity was measured in activity buﬀer with 1mM phenyl
acetate by monitoring the absorbance at 270nm (C =
700OD/M). Activities were expressed as U/L for paraoxon
and kU/L for phenyl acetate (1unit = 1nmol of paraoxon or
1μmol of phenyl acetate hydrolyzed per minute per 1mL of
undiluted serum).
All the measures of PON1 activity were performed in
duplicate, and all the coeﬃcients of variations were less than
5%.
2.4. PON1 Gln192Arg and Leu55Met Polymorphism Analysis.
GenomicDNAwasextractedfromwhole-bloodsamplesbya
phenol-chloroform procedure, and subjects were genotyped
according to a previously described multilocus assay [24].
PON1genotypeswereavailablefor264/293(90.1%)subjects.
2.5. Statistics. Calculations were performed with SPSS 17.0
statistical package (SPSS Inc., Chicago, Ill). Distributions of
continuous variables in groups were expressed as means ±
standard deviation. Statistical analysis on skewed variables,
like paraoxonase activity, was computed on the correspond-
ing log-transformed values. However, for the sake of clarity,
nontransformed data are reported in the results. Quanti-
tative data were assessed using Student’s t-test or analysis
of variance (ANOVA). Correlations between quantitative
variables were assessed using Pearson’s correlation test.
Qualitative data were analyzed with the χ2-test and with χ2
for linear trend analysis when indicated. A value of P<0.05
was considered statistically signiﬁcant. Statistical power was
estimated by means of Altmann nomogram.
Within each group examined, the frequencies of the
genotypes associated with each of the polymorphisms were
compared by the χ2-test with the values predicted on the
basis of the Hardy-Weinberg equilibrium.
The strength of association of PON1 activity with MS
was evaluated by including all the four assessed activities
in a multiple regression model with a forward-stepwise
variable selection that lastly was adjusted also for HDL
and Apo A-I concentrations. The combined eﬀect of MS
and DEPCyMCase activity in determining CAD risk was
estimated calculating the odds ratios with 95% CIs by
multiple logistic regression after adjustment for traditional
cardiovascular risk factors not included in MS cluster (i.e.,
age,sex,smoke,andLDLcholesterol).Finally,thecorrelation
between DEPCyMCase activity and LDL cholesterol/Apo B
ratio was evaluated by means of a linear regression analysis
model adjusted for age, sex, and HDL concentration.
3. Results and Discussion
3.1. Results. The clinical characteristics of the study pop-
ulation divided on the basis of MS diagnosis are reported
in Table 1.S u b j e c t sw i t h( n = 88) or without MS (n =
205) diﬀered for several characteristics, not only related to
MS cluster. As expected, MS was more represented among
CAD patients. Moreover, MS subjects presented a lower
LDL cholesterol/Apo B ratio. All the four investigated PON1
activities (TBBLase, DEPCyMCase, arylesterase, and paraox-
onase activities) were signiﬁcantly lower in MS subjects,
while no signiﬁcant diﬀerence was found for NLA, nor for
PON1 genotypes distribution, which respected the Hardy-
Weinberg equilibrium (Table 1). No signiﬁcant diﬀerence
was found between CAD subjects with or without MI for
PON1 activities nor for MS distribution (data not shown).
Ranking the study population on the basis of MS abnor-
malities, PON1 activity levels, as well as HDL and Apo A-I
concentrations, and LDL-cholesterol/Apo B ratio decreased
progressively by increasing the number of metabolic dis-
turbances (Table 2). In particular, DEPCyMCase activity
presented a very high signiﬁcant association with both MS
diagnosis (20.60 ±6.05 versus 23.8 ±5.6mU/mL in subjects
with or without MS, resp., P = 1.58 ×10
−5) and the number
of metabolic disturbances (P for linear trend = 3.84×10
−6).
Including all the PON1 activities in a regression model with
a forward-stepwise variable selection, only DEPCyMCase
activity remained a signiﬁcant predictor of MS (OR for
1mU/mL increase = 0.90 with 95% CI 0.86–0.95; P<0.001).
Noteworthy, this association was independent of HDL and
ApoA-Ilevels(ORfor1mU/mLincrease =0.93with95%CI
0.88–0.98; P = 0.004) and of both PON1 genotypes (OR for
1mU/mLincrease=0.92with95%CI0.86–0.99;P = 0.017).
Consistently with the last outcome, by stratifying the
study population on the basis of MS diagnosis and HDL
levels, which were considered as a dichotomic variable on
the basis of MS-related threshold level, subjects with low
HDL levels but without MS had a higher DEPCyMCase
activity than subjects with equally low HDL levels and MS
(Figure 1(a)). Interestingly, subjects with low HDL levels but
without MS presented a DEPCyMCase activity comparable
with that of subjects with high HDL levels and without
MS (Figure 1(a)). On the other hand, subjects with high
HDL levels but with MS showed a trend versus lower
DEPCyMCase activity compared to those with high HDL
levels and without MS, even if this diﬀerence did not reach
statistical signiﬁcance. Noteworthy, no diﬀerence in HDL or
Apo A-I concentration appeared to justify such results in the
above-mentioned four subgroups. Indeed, within the groups
with either low or high HDL levels, MS diagnosis was not
associated with additional diﬀerences in HDL and Apo A-
I concentrations (Figures 1(b) and 1(c)), thus supporting
an HDL-independent, Apo A-I-independent association of
DEPCyMCase activity with MS.4 Experimental Diabetes Research
Table 1: Characteristics of the study population, with or without metabolic syndrome (MS).
Characteristics MS-free (n = 205) MS (n = 88) P
Age (years) 60.9 ±9.36 0 .8 ±9.6N S ∗
Male sex (%) 59.5 42.0 0.006†
Coronary Artery Disease (%) 61.0 79.5 0.002†
BMI (kg/m2)2 5 .5 ±2.92 8 .7 ±5.1 <0.001∗
Hypertension (%) 57.1 89.8 <0.001†
Smoking (%) 52.8 54.9 NS †
Diabetes (%) 7.8 46.5 <0.001†
Glucose (mmol/L) 5.40 ±0.98 7.01 ± 2.29 <0.001∗
Creatinine (¯mol/L) 90.1 ±64.28 9 .4 ± 21.9N S ∗
Total cholesterol (mmol/L) 5.16 ±1.13 5.29 ± 1.19 NS∗
LDL-cholesterol (mmol/L) 3.18 ±0.95 3.33 ± 1.11 NS∗
HDL-cholesterol (mmol/L) 1.35 ±0.34 1.07 ± 0.31 <0.001∗
Triglycerides (mmol/L) 1.47 ±0.65 2.33 ± 0.98 <0.001∗
Apo A-I (g/L) 1.30 ±0.26 1.13 ± 0.23 <0.001∗
Apo B (g/L) 0.98 ±0.24 1.08 ± 0.28 0.003∗
TBBLase activity (U/mL) 3.45 ±0.98 3.02 ± 1.02 0.001∗
DEPCyMCase activity (mU/mL) 23.83 ±5.65 20.60 ±6.05 <0.001∗
Paraoxonase activity (U/L) 120.8 ±79.1 102.6 ±71.5 0.030∗
Arylesterase activity (kU/L) 101.3 ±31.48 6 .8 ± 32.5 <0.001∗
Normalized lactonase activity 145.0 ±24.3 146.1 ±35.0N S ∗
PON1 Gln192Arg ‡
Gln/Gln 50.3 45.6
Gln/Arg 40.0 49.4 NS†
Arg/Arg 9.7 5.1 ∗
PON1 Leu55Met‡
Leu/Leu 38.0 38.0
Leu/Met 48.9 44.3 NS†
Met/Met 13.1 17.7
∗by t-test; †by χ2 test; ‡PON1 genotype data were available for 264/293 (90.1%) subjects, that is, 185 MS-free and 79 with MS; NS: no signiﬁcant.
Table 2:Serumparaoxonase(PON1)activities,HDLcholesterol,andapolipoproteinA-I(ApoA-I)concentrationsandLDLcholesterol/Apo
B ratio according to the number of metabolic syndrome (MS) abnormalities.
0MSelement
(n = 35)
1MSelement
(n = 78)
2MS
elements
(n = 92)
3MS
elements
(n = 50)
4MS
elements
(n = 31)
5MS
elements
(n = 7)
P∗
TBBLase activity
(U/mL) 3.60 ±1.38 3.46 ±0.95 3.38 ±0.80 3.08 ±0.99 2.98 ±1.13 2.69 ±0.56 <0.001∗
DEPCyMCase
activity (mU/mL) 24.49 ±7.62 23.97 ±5.90 23.45 ±4.49 21.74 ±5.96 19.36 ±6.23 17.92 ±4.37 <0.001
Paraoxonase
activity (U/L) 128.4 ±103.7 118.8 ±69.2 119.5 ±77.1 102.2 ±63.0 103.6 ±89.7 101.4 ±38.3N S
Arylesterase
activity (kU/L) 106.3 ±35.7 101.3 ±31.19 9 .3 ±30.08 9 .1 ±34.08 5 .6 ±32.37 6 .0 ±21.0 <0.001
Normalized
Lactonase Activity 145.4 ±23.3 145.3 ±24.4 144.7 ±24.9 140.8 ±31.9 152.8 ±39.1 154.3 ±34.7N S
HDL cholesterol
(mmol/L) 1.25 ±0.26 1.19 ±0.25 1.14 ±0.25 1.05 ±0.23 0.97 ±0.15 0.83 ±0.19 <0.001
Apo A-I(g/L) 1.38 ±0.25 1.31 ±0.27 1.27 ±0.26 1.18 ±0.25 1.09 ±0.17 0.93 ±0.21 <0.001
LDL
cholesterol-to-Apo
B ratio (mmol/g)
3.32 ±0.43 3.31 ±0.73 3.21 ±0.65 3.04 ±0.65 2.97 ±0.45 2.88 ±0.57 0.001
∗by ANOVA with polynomial contrast for linear trend.Experimental Diabetes Research 5
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Figure 1: DEPCyMCase activity (a), HDL cholesterol (b), and apolipoprotein A-I concentration (c) according to high/low HDL cholesterol
levels and metabolic syndrome (MS) diagnosis (b). Low HDL-cholesterol concentrations are deﬁned on the basis of ATP-III criteria for MS-
diagnosis, that is, <1.03mmol/L for males or <1.29mmol/L for females. †Signiﬁcantly lower than no-MS with high or low HDL (P<0.01
by Tukey post-hoc comparison). ‡Signiﬁcantly lower than high HDL with or without MS (P<0.01 by Tukey post-hoc comparison).
Considering that MS is linked to an increased risk of
CAD and that an association of low DEPCyMCase activity
with CAD has been previously found in the same study
population[21],ananalysisaboutpotentialcombinedeﬀects
on CAD risk was performed. In a multiple logistic regres-
sion model, both MS and DEPCyMCase activity remained
signiﬁcantly associated with CAD (OR for MS = 2.17 with
95% CI 1.19–3.97, P = 0.012; OR for 1mU/mL increase
of DEPCyMCase activity = 0.95 with 95% CI 0.91–0.99,
P = 0.033). After stratifying the study population on the
basis of MS diagnosis and DEPCyMCase activity tertiles, the
statistical analysis highlighted a progressive increase of CAD
diagnosis prevalence among subjects without MS but within
the highest DEPCyMCase activity tertile group, compared
to those with MS and within the lowest DEPCyMCase
activity tertile (Figure 2(a)). Considering subjects without
MS and with the highest DEPCyMCase activity tertile as
reference group, subjects with MS and low DEPCyMCase
activity presented a marked increase of CAD risk, even after
adjustments for the classical cardiovascular risk factors not
included in MS cluster (OR 4.34 with 95% CI 1.44–13.10,
Figure 2(b)), while no signiﬁcant increase of CAD risk was
foundforthosewithMSbuthighDEPCyMCaseactivity(OR
1.45 with 95% CI 0.47–4.46). Such results were conﬁrmed
also by including PON1 genotypes in the regression model
(for subjects with MS and low DEPCyMCase activity: OR
4.67 with 95% CI 1.12–15.15).
An analysis on LDL cholesterol/Apo B ratio was also
performed. The LDL cholesterol/Apo B ratio was used as
a surrogate marker for small and dense LDLs, where the
lowerratiossuggestedahigherprevalenceofthistypeofLDL
particles. A low LDL cholesterol/Apo B ratio was associated
with both CAD (3.09 ± 0.57 versus 3.36 ± 0.60mmol/g in
CAD-free, P<0.001) and MS (3.00 ± 0.57 versus 3.26 ±
0.59mmol/g in MS-free, P = 0.001). Furthermore, the ratio
progressively decreased with the consensual increase of the6 Experimental Diabetes Research
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Figure 2: Prevalence of subjects with coronary artery disease (CAD) according to metabolic syndrome (MS) diagnosis and DEPCyMCase
activity (a) and the relative ORs for CAD in a multiple adjusted regression model considering subjects without MS and within the highest
DEPCyMCaseactivity tertile as reference group (b). ∗B y multiple logistic regression adjusted for classical CAD risk factors not included in
MS deﬁnition, that is, sex, age, smoke and LDL cholesterol.
number of metabolic disturbances (Table 2). DEPCyMCase
activity showed also a positive correlation with LDL choles-
terol/Apo B ratio (Pearsons’coeﬃcient 0.165, P = 0.008)
that remained signiﬁcant even after a regression model
adjusted for age, gender, and HDL levels (standardized beta-
coeﬃcient 0.158, P = 0.014) was performed. By stratifying
the study population on the basis of MS diagnosis and DEP-
CyMCase activity tertiles, there was a progressive decrease of
LDL cholesterol/Apo B ratio from subjects without MS and
within the highest DEPCyMCase activity tertile toward those
subjects who instead had MS and were within the lowest
DEPCyMCase activity tertile. These ﬁndings were observed
both when the analysis was performed in the whole study
population (Figure 3(a)) and even after the exclusion of
subjects taking lipid-lowering therapy (Figure 3(b)).
4. Discussion
The current study, consistently with some previous obser-
vations [18, 19], shows a substantial impairment of PON1
activities in patients aﬀected by MS.
MS is characterized by a constellation of metabolic abno-
rmalities that altogether lead to an increased risk of cardi-
ovascular diseases. Although there is a substantial disagree-
ment over the terminology and diagnostic criteria of MS and
even some controversies exist about whether MS is a true
syndrome or a mixture of various phenotypes [1–3], it is un-
deniable that the clustering of MS abnormalities occurs join-
tly more often than by chance alone, suggesting the possi-
bility of an underlying, common pathogenesis [1]. A biolog-
ically plausible hypothesis proposes that MS presents when
an excess of body fat accumulates in subjects with a speciﬁc
metabolic susceptibility which seems likely represented by
insulin resistance [2]. On the other hand, MS is also known
to be associated with a prooxidant and proinﬂammatory
status. Moreover, oxidative stress is considered to play a
pivotalroleinMSpathophysiology,favouringatherosclerotic
damage and increasing CAD risk [4].
PON1 is a HDL-associated, pleiotropic enzyme and may
play a role in several diﬀerent pathways: from the protection
against oxidative damage and lipid peroxidation to the con-
tribution to innate immunity processes and from the detoxi-
ﬁcation of reactive molecules and/or xenobiotic compounds
to drug bioactivation (e.g., clopidogrel) [14, 25–27]. More
speciﬁcally, PON1 is capable of protecting lipoproteins from
lipid peroxidation by degrading speciﬁc oxidized cholesteryl
esters and phospholipids, and antioxidant properties of HDL
have been attributed, at least partially, to PON1 [25, 28, 29].
On the other hand, PON1 can be, in turn, inactivated by oxi-
dative stress and oxidized lipids [30]. Thus, there are many
biologically plausible reasons linking the pro-oxidant, HDL-
poor MS with the anti-oxidant, HDL-associated PON1.
In the ﬁrst study linking PON1 and MS, Senti and
coworkers observed a progressive decrease of paraoxonase
activity by increasing the number of MS disturbances [18].
Concomitantly, a progressive increase of lipid peroxides con-
centration was observed, so that the authors hypothesized
that a greater degree of severity of MS is associated with an
increased oxidative stress which inactivates PON1 function.
On the other hand, they emphasized also the possibility that
low PON1 function fails an eﬃcient protection against MS-
related oxidative damage that cannot be excluded [18]. Later
on, those results were conﬁrmed by Blatter Garin and col-
leagues, who found a low paraoxonase activity and a reducedExperimental Diabetes Research 7
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Figure 3: LDL cholesterol/Apo B ratio according to metabolic
syndrome (MS) diagnosis and DEPCyMCase activity in the whole
population (a) (n = 293) and in subjects without lipid-lowering
therapy (b) (n = 162).
PON1 mass in patients with MS [19]. These authors also
found that MS patients had a decreased LDL cholesterol/Apo
B ratio, indicative of the presence of small, dense, oxidized,
and proatherogenic lipoprotein particles [19].
Our study extends such ﬁndings also for the novel PON1
assays utilized, the DEPCyMCase and TBBLase activity.
Moreover,themostsigniﬁcantassociationfoundinouranal-
ysis was that with DEPCyMCase activity, which is considered
the best surrogate marker of PON1 concentration, since,
diﬀerently from the other assay to test PON1 activities, it
is not inﬂuenced by PON1 genotype nor is it stimulated by
HDL binding [20].
Although it could be argued that MS-related, low PON1
concentration is merely an epiphenomenon of low level of
HDLs (i.e., the plasma carriers of PON1), our analysis does
not support this point of view, the association of DEP-
CyMCase activity with MS being independent of both HDL
and Apo A-I levels. This HDL-independent association is
further emphasized by observing that subjects with low HDL
level but without MS appeared to have a “normal” not
reduced DEPCyMCase activity, while those with high HDL
level but with MS tended to have a reduced DEPCyM-
Case activity (Figure 1(a)). Taking all together, these results
suggest that a low DEPCyMCase activity, that is, a low
PON1 concentration, is characteristic of MS, independently
of low HDL concentration. Moreover, they invite to take
into account not only HDL quantity but also HDL quality,
which could be reﬂected, at least in part, by PON1 concen-
tration/activity. It is noted, in this regard, that subjects with
lowHDLbutwithoutMSmayhaveasmallamountof“high-
quality” HDLs, while subjects with high HDL levels but
with MS may have a large amount of “low-quality” HDLs.
The relevance of considering HDL quality and not only
its quantity has been indirectly emphasized by the failure
of the cholesteryl ester transfer protein (CETP) inhibitor,
torcetrapib, to improve cardiovascular clinical end points.
It has been in fact reported that torcetrapib, in spite of its
demonstrated eﬃciency to elevate HDL concentration, even-
tually leads instead to an increased cardiovascular morbidity,
even if also other oﬀ-target adverse eﬀects for CAD risk (e.g.,
bloodpressureelevation)havebeenrelatedtotorcetrapibuse
[31,32].However,inanycase,theseresultshaveunderscored
the intricacy of HDL metabolism, with functional quality
perhaps being more important than the circulating quantity
of HDL [33, 34]. Indeed, both quantitative and qualitative
changes to lipoprotein proﬁles may lead to an increased
CAD risk and PON1 could be considered as a potential
marker of HDL quality, being linked to the antioxidant, anti-
inﬂammatory properties of HDL.
Accordingly with this last consideration, in our study
PON1 appears to inﬂuence the MS-related risk of CAD.
Certainly, an additive eﬀect between MS and PON1 levels
(marked by DEPCyMCase activity) should be considered in
determining CAD risk, which increased progressively from
subjectswithoutMSandwithhighPON1levelstothosewith
MS and low PON1 levels. Remarkably, subjects with MS but
still high PON1 levels did not present a signiﬁcant increase
of CAD risk. This result is consistent with a previous study
showing that an increased expression of human PON1 in a
mousemodelofMSinhibitedthedevelopmentofatheroscle-
rosis, probably by reducing the amount of oxidized LDL
in both plasma and atherosclerotic plaque [35]. Moreover,
it is worthy of note that, in our study population, there
was a signiﬁcant, positive correlation between DEPCyMCase
activity and LDL cholesterol/Apo B ratio, suggestive of high
PON1 levels associated with low levels of small, dense, and
oxidized LDL. Remarkably, LDL cholesterol/Apo B ratio
trend across the MS-DEPCyMCase activity stratiﬁcation
groups (Figure 3) was impressively consistent with that of
CAD risk (Figure 2). Taken together these results, we are
tempting to speculate that an adequate function of PON1
may counterbalance some of MS-related, harmful eﬀects at
vascular level, probably by reducing oxidative stress and lipid
peroxidation, and thus protect against MS-associated risk of
CAD. If this hypothesis is true, by restoring PON1 function,
there could be a possibility for a new therapeutic tool for
cardiovascular diseases, with particular advantageous eﬀects
inhigh-riskpatients,suchsubjectswithMS.However,PON18 Experimental Diabetes Research
reductionmaybemerelytheresultofamoreextensivePON1
consumption/inactivation during conditions characterized
by increasing severity of oxidative stress, like a more
advanced MS [19] or a clinically evident CAD. Therefore,
further studies are needed to address the issue whether
PON1 reduction could be a pathogenic, contributory factor
to increased risk of CAD in MS or that reduction would
be simply the consequence of ancillary enzyme consump-
tion/inactivationduetoCAD/MS-associatedoxidativestress.
4.1. Study Limitations. There are some signiﬁcant caveats to
the present study. The retrospective case-control design, the
small number of enrolled subjects, and the lack of some clin-
ical data, such as the waist circumference value, are possible
limitations of this study. However, despite the relatively low
sample size of our study population, the statistical power
of the analysis for DEPCyMCase activity diﬀerence between
MS and MS-free subjects was >90% by Altmann nomogram
with a signiﬁcance level at 0.05. As further experimental
limitation, it should be underlined that the DEPCyMCase
activity is only a surrogate marker of PON1 concentration
and that we did not perform a direct PON1 quantiﬁcation
by ELISA. However, in a previous study the DEPCyMCase
assay has been shown to provide information similar to
PON1 ELISA assay [20]. Also LDL cholesterol/Apo B ratio is
regarded as a surrogate marker of small and dense LDL and,
in addition, Apo B was measured in whole serum, although
it is known to essentially reﬂect Apo B in LDL. On the other
hand, a remarkable strength of this study is represented by
theangiographyevaluationofthecoronaryarterybed,which
allows a clear-cut deﬁnition of the clinical phenotype and
avoids the possibility to include in the control group subjects
with subclinical, but signiﬁcant CAD.
5. Conclusions
Insummary,ourresultsshowthatPON1activities,including
those evaluated by means of novel substrate assays (TBBL
and DEPCyMC), are impaired in MS. In particular, these
assays suggest that a low PON1 concentration, as indicated
by the low DEPCyMCase activity, is characteristic of MS
cluster, independently of HDL concentration. Moreover,
DEPCyMCase activity appears to interact with MS in
determining the risk of CAD, with data suggesting that
this association may be also related to the prevalence of
small, dense, and oxidized LDL. More precisely, a high
DEPCyMCase activity (i.e., a high PON1 concentration)
seems protective for CAD risk in subjects with MS, while the
highest risk for CAD was observed among subjects with MS
and concomitant low levels of DEPCyMCase activity (i.e., a
lowPON1concentration).Certainly,astatisticallysigniﬁcant
association does not mean a link of causality. Nonetheless,
PON1 assays seem to add more important information
than the simple HDL quantity assessment. According to this
hypothesis of heterogeneous HDL-related eﬀects, a recent
study demonstrated that in contrast to HDL from healthy
subjects, HDL from patients with CAD does not have
endothelial anti-inﬂammatory eﬀects and does not stimulate
endothelial repair because it fails to induce endothelial NO
production [36]. Mechanistically, the reduction of HDL-
associated PON1 activity appears to lead to inhibition of
eNOS activation and the subsequent loss of the endothelial
antiinﬂammatory and endothelial repair-stimulating eﬀects
of HDL [36], thus supporting the concept that the cardiovas-
cular impact of HDL is not simply related to its abundance
[37]. Indeed, HDL cholesterol is only an integrative but
nonfunctional measure of lipoproteins, and, therefore, novel
biomarkers reﬂecting the functionality of HDL particles are
needed to assess and better monitor cardiovascular risk [34],
in particular in the presence of conditions at high CAD risk
such as the case of MS. PON1 assays could be potentially
considered as such new diagnostic tools while further studies
are needed to address this intriguing issue.
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